These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 22465543

  • 1. Organic nanocarriers for cancer drug delivery.
    López-Dávila V, Seifalian AM, Loizidou M.
    Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nanocarriers for cancer-targeted drug delivery.
    Kumari P, Ghosh B, Biswas S.
    J Drug Target; 2016 Aug; 24(3):179-91. PubMed ID: 26061298
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Advances in polymeric micelles for drug delivery and tumor targeting.
    Kedar U, Phutane P, Shidhaye S, Kadam V.
    Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Active targeting strategies for anticancer drug nanocarriers.
    Basile L, Pignatello R, Passirani C.
    Curr Drug Deliv; 2012 May; 9(3):255-68. PubMed ID: 22452402
    [Abstract] [Full Text] [Related]

  • 10. Liposomal nanomedicines.
    Fenske DB, Cullis PR.
    Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
    [Abstract] [Full Text] [Related]

  • 11. Improvement of drug safety by the use of lipid-based nanocarriers.
    Lim SB, Banerjee A, Önyüksel H.
    J Control Release; 2012 Oct 10; 163(1):34-45. PubMed ID: 22698939
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Stimuli-sensitive nanopreparations for combination cancer therapy.
    Jhaveri A, Deshpande P, Torchilin V.
    J Control Release; 2014 Sep 28; 190():352-70. PubMed ID: 24818767
    [Abstract] [Full Text] [Related]

  • 17. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
    Sultana S, Khan MR, Kumar M, Kumar S, Ali M.
    J Drug Target; 2013 Feb 28; 21(2):107-25. PubMed ID: 22873288
    [Abstract] [Full Text] [Related]

  • 18. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV.
    Biomaterials; 2009 Aug 28; 30(23-24):3986-95. PubMed ID: 19427688
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F, Ucakar B, Magotteaux N, Brewster ME, Préat V.
    Int J Pharm; 2010 Jun 15; 392(1-2):20-8. PubMed ID: 20226846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.